As of 14 Oct 2026, Celea Therapeutics has raised $180M across 1 verified round on record; latest: $180 million funding round, announced 2 Jul 2026.
Celeatx offers investigational medications, particularly deupirfenidone, for the treatment of idiopathic pulmonary fibrosis (IPF).
celeatx.comBiotech
1 source
The source also mentions two other unnamed funds, which cannot be identified or listed by name.
Published by hand (biopharmadive.com): "the biotech, which announced a $180 million raise on July 2, 2026, is one of several working on new pulmonary fibrosis drugs.": biggest-rounds completeness (K): the round's own page (company, lead investor or trade press) states it
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Funding round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $180M | 2026-07-02 | not stated | No recent discussion |
1 source [ VERIFIED · CORRECTED ] read against 1 source The source also mentions two other unnamed funds, which cannot be identified or listed by name. Published by hand (biopharmadive.com): "the biotech, which announced a $180 million raise on July 2, 2026, is one of several working on new pulmonary fibrosis drugs.": biggest-rounds completeness (K): the round's own page (company, lead investor or trade press) states it | ||||